PARIS, Oct. 11, 2017 (GLOBE NEWSWIRE) -- BIOPHYTIS (Euronext Growth Paris:ALBPS), a biotechnology company specializing in the development of drug candidates to treat age-related diseases, announces entry into definitive agreements for a € 10.4 million capital raise via the issuance of new ordinary shares without shareholders’ preferential subscription rights and reserved to institutional investors in Europe and the United States.

Stanislas Veillet, Chairman and Chief Executive Officer of BIOPHYTIS, said: "We are pleased to announce that we successfully receive commitment for capital raise, which provides BIOPHYTIS with the means to finance the clinical development programs of its two main drug candidates in age-related diseases. This raise will enable us to significantly strengthen our shareholder structure, notably thanks to the support of leading American and European investors, who have shown their confidence in the potential of our therapeutic approach."

Invest Corporate Finance acted as global coordinator for the operation. Invest Securities and H.C. Wainwright & Co. acted as exclusive placement agent for the offering in Europe and the United States, respectively.

The funds raised will provide BIOPHYTIS with additional resources to continue its clinical development in age-related diseases, such as Sarcopenia and Age-Related Macular Degeneration, and will especially be used to finance:

  • The launch of the 26-week, multi-center, international and interventional study SARA-INT in 334 sarcopenic patients for which the IND application for FDA approval has been filed in the United States; and
  • The MACA-PK multi-center, international clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of Macuneos in patients with dry intermediate AMD

The capital raise by means of a private placement consists in the issuance of 1,989,000 new ordinary shares at a price of €5.25 per share, representing a discount of 9% based on the weighted average price over the last 10 trading days before pricing. The total amount of the operation is 10,442,500 million euros, representing 20% of the share capital of the Company. The new ordinary shares will be the subject of a request for admission to trading on the Euronext Growth market to Euronext.

The Company’s Board of Directors approved this capital increase at its meeting of October 10, 2017.

The capital will be increased via the issuance of new shares without shareholders’ preferential subscription rights, pursuant to Article 225-136 of the French Commercial Code (by private placement of up to 20% of the share capital). Pursuant to Article 211-3 of the AMF’s general regulations, this offer of financial securities did not result in a prospectus subject to AMF approval.

BIOPHYTIS SA (, founded in 2006, develops drug candidates targeting diseases of aging. Using its technology and know-how, BIOPHYTIS has begun clinical development of innovative therapeutics to restore the muscular and visual functions in diseases with significant unmet medical needs. Specifically, the company is advancing two lead products into mid-stage clinical testing this year: Sarconeos (BIO101) to treat sarcopenic obesity and Macuneos (BIO201) to treat dry age-related macular degeneration (AMD).

The business model of BIOPHYTIS is to ensure the conduct of the project until clinical activity in the patient is proven, then to license the technologies in order to continue the development in partnership with a pharmaceutical laboratory.

The company was founded in partnership with researchers at the UPMC (Pierre and Marie Curie University) and also collaborates with scientists at the Institute of Myology, and the Vision Institute.

BIOPHYTIS is listed on the Euronext Growth market of Euronext Paris (ALBPS; ISIN: FR0012816825).

For more information:

Follow us on Twitter @biophytis

BIOPHYTIS is eligible for the SMEs scheme

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the Listing Prospectus upon the admission of Company’s shares for trading on the regulated market Euronext Growth of Euronext Paris filed with the AMF, which is available on the AMF website (www.amf- or on BIOPHYTIS’ website (

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in BIOPHYTIS in any country. Items in this press release may contain forward-looking statements involving risks and uncertainties. The Company’s actual results could differ substantially from those anticipated in these statements owing to various risk factors which are described in the Company’s prospectus. This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall prevail.

Stanislas VEILLET
Tel: +33 (0) 1 41 83 66 00


Citigate Dewe Rogerson
Presse internationale & Investisseurs
Laurence BAULT/Antoine DENRY
Tel: +33 (0)1 53 32 84 78
Mob: +33(0)6 64 12 53 61

LifeSci Advisors
Managing Director, Europe
Tel: +41 79 367 6254